EUVIMEDEUVIMED entdecken
Crossref

Seraph-100 hemoperfusion for management of severe COVID-19: Assessment of serum and plasma analytes pre- and post-filtration

Michael Rouse, Eric R Gann, Joost Brandsma, Victor A Sugiharto, Henry Robertson, Pavol Genzor, Hua-Wei Chen, Mark P Simons, Seth A Schobel, Josh G Chenoweth, Sarah A Jenkins, Danielle V Clark und 9 weitere

Blood Purification · 2024

DOI: 10.1159/000542995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Purification, 2024. Verfasst von Michael Rouse und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: COVID-19, Hemoperfusion, SARS-CoV-2.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We report an Intervention/outcome study of 33 severe COVID-19 subjects who received Seraph100 Microbind Affinity Blood Filter (Seraph 100) hemoperfusion therapy (15 survivors, 18 non-survivors) under emergency authorization from the FDA. Our objective was to determine if Seraph 100 hemoperfusion reduces SARS-CoV-2 RNA titers and/or markers of inflammation and/or epi/endothelial damage.a Methods Viral RNA and 78 protein analytes related to endothelial/epithelial damage and/or inflammation were quantified in systemic blood samples from 33 severe COVID-19 subjects collected upon ICU admission and then immediately before and after blood passed through the heparin-based Seraph 100 filter at two time points on the first day of hemoperfusion. Viral RNA titers were quantified using droplet-digital PCR. Protein analytes were quantified using multiplex/multi-analyte panels on MesoScale Discovery and ProteinSimple-Ella platforms.

Results

A total of 15/33 subjects had detectable viral RNA in baseline samples (shortly after ICU admission). These initial viremia levels were low, and they did not change uniformly post-perfusion. Five of 55 protein analytes that were up-regulated 1.4-120X at ICU admission relative to healthy controls showed significant decreases across the filter during the indicated time points on the first day of hemoperfusion: IP-10/CXCL10, fms-like tyrosine kinase (Flt-1), MIG/CXCL9, Hepatocyte Growth Factor (HGF) and receptor for advanced glycosylation end-products (RAGE). Paired t-tests identified 25 additional analytes that showed significant decreases (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HemoperfusionSARS-CoV-2HumansMaleMiddle AgedFemaleRNA, ViralAgedBiomarkersAdultIntensive Care UnitsViral Load

Stichwörter der Autor:innen

Acute respiratory distress syndromeBlood purificationCOVID-19Seraph 100 hemoperfusionSevere acute respiratory syndrome corona virus-2

Substanzen

RNA, ViralBiomarkers

Autor:innen und Institutionen

  • Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
  • Uniformed Services University (USU) Surgical Critical Care Initiative (SC2i), Bethesda, Maryland, USA.
  • Austere Environments Consortium for Enhanced Sepsis Outcomes (ACESO), Bethesda, Maryland, USA.
  • Naval Medical Research Command, Silver Spring, Maryland, USA.

Zitieren

APA

Rouse, M., Gann, E. R., Brandsma, J., Sugiharto, V. A., Robertson, H., Genzor, P., Chen, H. W., Simons, M. P., Schobel, S. A., Chenoweth, J. G., Jenkins, S. A., Clark, D. V., Della Volpe, J., Chitty, S., Rivera, I. M., Lewis, M., Park, C., Parikh, A., Vir, P., …, & Pratt, K. P. (2024). Seraph-100 hemoperfusion for management of severe COVID-19: Assessment of serum and plasma analytes pre- and post-filtration. Blood Purification. https://doi.org/10.1159/000542995

Vancouver

Rouse M, Gann ER, Brandsma J, Sugiharto VA, Robertson H, Genzor P, et al. Seraph-100 hemoperfusion for management of severe COVID-19: Assessment of serum and plasma analytes pre- and post-filtration. Blood Purification. 2024. doi:10.1159/000542995

BibTeX
@article{Rouse2024,
  author = {Rouse, Michael and Gann, Eric R and Brandsma, Joost and Sugiharto, Victor A and Robertson, Henry and Genzor, Pavol and Chen, Hua-Wei and Simons, Mark P and Schobel, Seth A and Chenoweth, Josh G and Jenkins, Sarah A and Clark, Danielle V and Della Volpe, Jeffrey and Chitty, Stephen and Rivera, Ian M and Lewis, Michael and Park, Caroline and Parikh, Amay and Vir, Pooja and Stewart, Ian J and Pratt, Kathleen P},
  title = {Seraph-100 hemoperfusion for management of severe COVID-19: Assessment of serum and plasma analytes pre- and post-filtration},
  journal = {Blood Purification},
  year = {2024},
  doi = {10.1159/000542995}
}
Kostenlos starten →